

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Meller, Michael

From: Meller, Michael
Sent: Friday, December 13, 2002 11:41 AM
To: STIC-Biotech/ChemLib
Subject: 09/827302

Sedlacek et al., Int. J. Immunopharmacol. , 9, (7), 1987, 841-50
Sedlacek et al., Cancer Immunol. Immunother 23 (3), 1986 192-199
Maiskii et al., Byull eksp biol med 84 (12) 1977 (recd 1978) 714-717
Knop et al., Immunology, 34 (2), 1978, 181-188
Gautam et al., Indian J. Med Res 64 (3), 1976 472-481
Sedlacek et al., Cancer Immunology Immunotherapy (cancer immunol. Immunother.) 1978 5/3 153-163
Mobley et al., Res. Commun. Chem. Path. Pharmacol. 1974, 9/1 155-162

Art found by reviewer

8/9/12 (Item 12 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

06086356 BIOSIS NO.: 000085049505

**TUMOR THERAPY OF NEOPLASTIC DISEASES WITH TUMOR CELLS AND
NEURAMINIDASE EXPERIMENTAL STUDIES ON CHESSBOARD VACCINATION IN
TRANSPLANTATION TUMORS**

AUTHOR: SEDLACEK H H; BENGELSDORFF K H; HAGMAYER G; SEILER F R

AUTHOR ADDRESS: RES. LAB. BEHRINGWERKE AG, 3550 MARBURG, W. GER.

JOURNAL: INT J IMMUNOPHARMACOL 9 (7). 1987. 841-850. 1987

FULL JOURNAL NAME: International Journal of Immunopharmacology

CODEN: IJIMD

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The therapeutic effect of intradermal (i.d.) **injection** of **tumor** cells mixed with VCN on growth of spontaneous metastases in transplantable **tumors** in mice (3-Lewis lung adenocarcinoma; B16-melanoma) and rats (R-3230 mammary adenocarcinoma) was investigated. Intradermal **injection** was done in a chessboard-like manner; increasing numbers (105, 106 and 107) of Mitomycin-treated **tumor** cells (M-TC) were each mixed with increasing amounts (10, 50 and 100 mU) of Vibrio cholerae **Neuraminidase** (VCN). These different mixtures were **injected** i.d. at different sites one day after resection of the primary **tumor** graft to mice and rats, suffering from minimal residual disease. The therapeutic effect of this so-called chessboard vaccination on mimimal residual disease was compared to that of the subcutaneous or i.d. **injection** of VCN-treated M-TC (105, 106, 107 or 108 cells) or of single mixtures of M-TC and VCN. The results that compared to VCN-treated M-TC or single mixtures of M-TC and VCN, chessboard vaccination is the only procedure that is therapeutically effective on metastasation of Lewis lung adenocarcinoma. The therapeutic effect could be abrogated by heat-inactivation of VCN. Incomplete chessboard vaccinations (105, 106, 107 **tumor** cells, each mixed with 5 mU VCN only) were likewise ineffective. However, **treatment** with incomplete chessboard vaccinations in combination with a low dose of cyclophosphamide (which is not immunosuppressive, but partly inhibits **tumor** growth) had a synergistic therapeutic effect on minimal residual disease of Lewis lung adenocarcinoma. In contrast, growth of metastases of B16-melanoma and R-3230 adenocarcinoma could not significantly be influenced by any of those **treatments**. The DTH response of **tumor** bearing animals against i.d. applied **tumor** cells was neither significantly enhanced by the admixture of enzymatically active VCN nor did the DTH response seem to be predictive for a **tumor**-therapeutic effect. Thomsen-Friedenreich antigens could serologically be detected on untreated cells of Lewis lung adenocarcinoma, B16-melanoma and R-3230 adenocarcinoma. Exposure of Thomsen-Friedenreich antigens after **treatment** with VCN was enhanced on cells of all **tumors** except Lewis lung adenocarcinoma. As chessboard vaccination only proved to be successful in Lewis lung adenocarcinoma, but not in the other **tumors**, it can be concluded that the exposure of Thomsen-Friedenreich antigen plays no decisive role in **tumor** therapy with **tumor** cells and VCN. Chessboard vaccination was tolerated without any side effects. **Tumor** enhancement was not observed. The mechanism underlying the therapeutic effect of chessboard vaccination is unknown. However, the experiments in combination with cyclophosphamide may indicate that by chessboard vaccination suppressor cells may be less stimulated.

DESCRIPTORS: MOUSE VIBRIO-CHOLERAES CYCLOPHOSPHAMIDE IMMUNOLOGIC-DRUG
ANTINEOPLASTIC-DRUG SPONTANEOUS METASTASIS IMMUNOTHERAPY

CONCEPT CODES:

02506 Cytology and Cytochemistry-Animal
10804 Enzymes-Methods
10808 Enzymes-Physiological Studies
12512 Pathology, General and Miscellaneous-Therapy (1971-)
15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial System
22018 Pharmacology-Immunological Processes and Allergy
24003 Neoplasms and Neoplastic Agents-Immunology
24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy
31000 Physiology and Biochemistry of Bacteria
34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology
36002 Medical and Clinical Microbiology-Bacteriology
10060 Biochemical Studies-General
10064 Biochemical Studies-Proteins, Peptides and Amino Acids

BIOSYSTEMATIC CODES:

04812 Vibrionaceae (1979-)
86375 Muridae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

Microorganisms
Bacteria
Animals
Chordates
Vertebrates
Nonhuman Vertebrates
Mammals
Nonhuman Mammals
Rodents

8/9/16 (Item 16 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

05615053 BIOSIS NO.: 000083088194

TUMOR THERAPY OF NEOPLASTIC DISEASES WITH TUMOR CELLS AND NEURAMINIDASE FURTHER EXPERIMENTAL STUDIES ON CHESSBOARD VACCINATION IN CANINE MAMMARY TUMORS

AUTHOR: SEDLACEK H H; HAGMAYER G; SEILER F R

AUTHOR ADDRESS: RES. LAB. OF BEHRINGWERKE AG, D-3550 MARBURG, FRG.

JOURNAL: CANCER IMMUNOL IMMUNOTHER 23 (3). 1986 (RECD. 1987). 192-199. 1986

FULL JOURNAL NAME: Cancer Immunology Immunotherapy

CODEN: CIIMD

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: The therapeutic effect of i. d. injection of tumor cells mixed with *Vibrio cholerae* neuraminidase (VCN) on tumor progression in dogs with spontaneous mammary tumors was investigated. The i. d. injections were performed in a chessboard-like manner: different numbers (105, 106, 107, and 108) of mitomycin-treated autologous tumor cells (M-TC) were each mixed with different amounts (10, 50, and 100 mU) of VCN. These different mixtures were injected i.d. at different sites in dogs on the day of resection of a part of multiple tumors. In a randomized prospective study in 71 dogs the effect of chessboard vaccination (autologous tumor cells and VCN) on the growth of the residual tumor mass was compared to chessboard-like treatments with mixtures of either autologous erythrocytes and VCN or autologous tumor cells and heat-inactivated VCN. The results show that: - chessboard vaccination induced regression (6 of 23) of spontaneous

mammary **tumors** in dogs. No dog died as a result of the **tumor** within an observation period of 1 year. The therapeutic effect of chessboard vaccination was dependent on the application of **tumor** cells and enzymatically active VCN. In contrast, control **treatment** with either heat-inactivated VCN or autologous erythrocytes instead of **tumor** cells did not induce any regressions. Some animals in both control groups died because of **tumor** growth (3/21 and 2/27 respectively). - The delayed type hypersensitivity (DTH) response of **tumor**-bearing animals against i. d. applied **tumor** cells was not significantly enhanced by the admixture of enzymatically active VCN, nor did the DTH response seem to be predictive of a therapeutic effect on the **tumor**. No difference in the DTH response of dogs to autologous **tumor** cells mixed with active or inactivated VCN or autologous erythrocytes mixed with active VCN could be found. - Thomsen-Friedenreich antigens were serologically detected on canine erythrocytes after **treatment** with VCN and on untreated cells of mammary **tumors** from dogs. Exposure of Thomsen-Friedenreich antigens after **treatment** with VCN was enhanced on canine mammary **tumors**. As chessboard vaccination proved to be unsuccessful when canine autologous erythrocytes were used instead of autologous **tumor** cells, it can be concluded that the exposure of Thomsen-Friedenreich antigen plays no decisive role in **tumor** therapy with **tumor** cells and VCN. - Chessboard vaccination was tolerated without any side effects. **Tumor** enhancement was never observed. Chessboard vaccination appears to be an effective and safe procedure for **tumor** therapy using **tumor** cells and VCN. The mechanism underlying the therapeutic effect of chessboard vaccination is completely unknown.

DESCRIPTORS: VIBRIO-CHOLERAES ANTINEOPLASTIC-DRUG IMMUNOLOGIC-DRUG
DELAYED-TYPE HYPERSENSITIVITY THOMSEN-FRIEDENREICH ANTIGEN

CONCEPT CODES:

16506 Reproductive System-Pathology
22018 Pharmacology-Immunological Processes and Allergy
24003 Neoplasms and Neoplastic Agents-Immunology
24004 Neoplasms and Neoplastic Agents-Pathology; Clinical Aspects; Systemic Effects
24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy
34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology
02506 Cytology and Cytochemistry-Animal
10808 Enzymes-Physiological Studies
12512 Pathology, General and Miscellaneous-Therapy (1971-)
15004 Blood, Blood-Forming Organs, and Body Fluids-Blood Cell Studies
31000 Physiology and Biochemistry of Bacteria

BIOSYSTEMATIC CODES:

04812 Vibrionaceae (1979-)
85765 Canidae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

Microorganisms
Bacteria
Animals
Chordates
Vertebrates
Nonhuman Vertebrates
Mammals
Nonhuman Mammals
Carnivores

02452732 BIOSIS NO.: 000066035276

APPLICATION OF NEURAMINIDASE FOR IMMUNO THERAPEUTIC ACTION ON
CHEMICALLY INDUCED CARCINOGENESIS

AUTHOR: MAISKII I N; AIRAPET'YAN G P; KOBRINSKII G D; TROITSKAYA N A;
GUDKOVA G B; AGAFONOVA T A; SOLOV'EV V D

AUTHOR ADDRESS: RES. LAB. EXP. IMMUNOBIOL., ACAD. MED. SCI. USSR, MOSCOW,
USSR.

JOURNAL: BYULL EKSP BIOL MED 84 (12). 1977 (RECD 1978) 714-717. 1977

FULL JOURNAL NAME: Byulleten' Eksperimental'noi Biologii i Meditsiny

CODEN: BEBMA

RECORD TYPE: Abstract

LANGUAGE: RUSSIAN

ABSTRACT: The effect of *Vibrio cholerae neuraminidase* (VCN) on the growth of dimethylbenzanthracene-induced sarcoma cells in the inbred CBA mice was investigated. The use of this preparation was started after the appearance of **tumors**. **Injection** of 50 units of VCN twice a week for 3 mo. was effective in the early stages of carcinogenesis. An increase of the life-span of mice compared with control animals was also observed in animals inoculated i.p. with induced syngeneic sarcoma cells pretreated with VCN and simultaneously **injected** (into the developing **tumor**) with sensitized lymphocytes received from syngeneic **tumor**-bearing mice. Lymphocytes were inoculated into the growing **tumor**. No positive effect ensued when lymphocytes inoculated into the **tumor** region were pretreated with VCN. Simultaneous i.p. inoculation of **neuraminidase** into the growing **tumor** and syngeneic induced sarcoma cells pretreated with this enzyme was most effective. Possibilities of application of **neuraminidase** under clinical conditions are discussed.

DESCRIPTORS: VIBRIO-CHOLERA MOUSE DI METHYL BENZ ANTHRACENE CARCINOGEN
SARCOMA LYMPHOCYTE TREATMENT ANTI NEOPLASTIC-DRUG IMMUNOL-DRUG

CONCEPT CODES:

- 10808 Enzymes-Physiological Studies
- 15008 Blood, Blood-Forming Organs and Body Fluids-Lymphatic Tissue and Reticuloendothelial System
- 18006 Bones, Joints, Fasciae, Connective and Adipose Tissue-Pathology
- 22012 Pharmacology-Connective Tissue, Bone and Collagen-Acting Drugs
- 22018 Pharmacology-Immunological Processes and Allergy
- 22501 Toxicology-General; Methods and Experimental
- 24003 Neoplasms and Neoplastic Agents-Immunology
- 24007 Neoplasms and Neoplastic Agents-Carcinogens and Carcinogenesis
- 24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy
- 34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology
- 38502 Chemotherapy-General; Methods; Metabolism
- 02506 Cytology and Cytochemistry-Animal
- 10060 Biochemical Studies-General
- 10064 Biochemical Studies-Proteins, Peptides and Amino Acids
- 11314 Chordate Body Regions-Abdomen (1970-)
- 12512 Pathology, General and Miscellaneous-Therapy (1971-)
- 15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies
- 22100 Routes of Immunization, Infection and Therapy
- 24005 Neoplasms and Neoplastic Agents-Neoplastic Cell Lines
- 31000 Physiology and Biochemistry of Bacteria
- 32500 Tissue Culture, Apparatus, Methods and Media
- 36002 Medical and Clinical Microbiology-Bacteriology

BIOSYSTEMATIC CODES:

- 08200 Pseudomonadales (1969-78)
- 86375 Muridae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

- Microorganisms
- Bacteria

Animals
Chordates
Vertebrates
Nonhuman Vertebrates
Mammals
Nonhuman Mammals
Rodents

8/9/31 (Item 31 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

02420053 BIOSIS NO.: 000066002594

STIMULATORY EFFECT OF VIBRIO-CHOLERAE **NEURAMINIDASE** ON THE ANTIBODY
RESPONSE TO VARIOUS ANTIGENS

AUTHOR: KNOP J; SEDLACEK H H; SEILER F R

AUTHOR ADDRESS: UNIV. HAUTKLIN., VON-ESMARCH-STR. 56, 4400 MUENSTER, W.
GER.

JOURNAL: IMMUNOLOGY 34 (2). 1978 181-188. 1978

FULL JOURNAL NAME: Immunology

CODEN: IMMUA

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: *V. cholerae neuraminidase* (VCN) splits off peripheral sialic acids from cell membranes. **Treatment** of **tumor** cells with VCN increases their immunogenicity. VCN may unmask hidden **tumor** specific antigens. VCN can affect the cell-cell interactions of immune cells in vitro and it seems possible that the enzyme may have a direct effect on the immune response to antigen in vivo. The present report describes the effect of VCN on the antibody response of mice to SRBC [sheep red blood cells], to antigens which do not contain peripheral neuraminic acid such as certain bacterial vaccines and rubella virus and to the soluble antigen BSA [bovine serum albumin]. VCN **injected** i.m. or i.p., but not i.v., together with the antigens increases the PFC [plaque forming cell] response to SRBC, the antibody response to various bacteria (*Escherichia coli*, *V. cholerae*, *Salmonella typhimurium*), the antibody response to rubella virus and inhibits tolerance induction by aggregate free BSA. The optimal dose required to stimulate the antibody response is between 0.5 and 50 units/animal. Possible mechanisms of the adjuvant activity of VCN are discussed.

DESCRIPTORS: MOUSE **TUMOR** SPECIFIC ANTIGENS SHEEP RED BLOOD CELLS
RUBELLA VIRUS TOGAVIRUS BOVINE SERUM ALBUMIN **ESCHERICHIA-COLI**
SALMONELLA-TYPHIMURIUM ADJUVANT ACTIVITY

CONCEPT CODES:

10804 Enzymes-Methods
13012 Metabolism-Proteins, Peptides and Amino Acids
24003 Neoplasms and Neoplastic Agents-Immunology
34502 Immunology and Immunochemistry-General; Methods
34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology
01054 Microscopy Techniques-Cytology and Cytochemistry
02506 Cytology and Cytochemistry-Animal
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
10068 Biochemical Studies-Carbohydrates
10508 Biophysics-Membrane Phenomena
11314 Chordate Body Regions-Abdomen (1970-)
13004 Metabolism-Carbohydrates
14501 Cardiovascular System-General; Methods
15004 Blood, Blood-Forming Organs and Body Fluids-Blood Cell Studies

17501 Muscle-General; Methods
22100 Routes of Immunization, Infection and Therapy
24005 Neoplasms and Neoplastic Agents-Neoplastic Cell Lines
24006 Neoplasms and Neoplastic Agents-Biochemistry
33506 Virology-Animal Host Viruses
36002 Medical and Clinical Microbiology-Bacteriology
36006 Medical and Clinical Microbiology-Virology

BIOSYSTEMATIC CODES:

03200 Animal Viruses (1969-78)
07200 Eubacteriales (1969-78)
08200 Pseudomonadales (1969-78)
85715 Bovidae
86375 Muridae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

Microorganisms
Viruses
Bacteria
Animals
Chordates
Vertebrates
Nonhuman Vertebrates
Mammals
Nonhuman Mammals
Artiodactyls
Rodents

8/9/35 (Item 35 from file: 5)
DIALOG(R) File 5: Biosis Previews(R)
(c) 2002 BIOSIS. All rts. reserv.

01977992 BIOSIS NO.: 000062068112

IMMUNO THERAPY OF METHYL CHOLANTHRENE INDUCED AND SPONTANEOUS TUMORS
IN MICE BY USE OF TUMOR VACCINE NEURAMINIDASE AND BCG

AUTHOR: GAUTAM S; AIKAT B K

JOURNAL: INDIAN J MED RES 64 (3). 1976 472-481. 1976

FULL JOURNAL NAME: Indian Journal of Medical Research

CODEN: IJMRA

RECORD TYPE: Abstract

ABSTRACT: Experiments were undertaken to evaluate the effectiveness of different immunotherapeutic measures on the appearance and growth of methylcholanthrene induced and spontaneous fibrosarcomas in syngeneic strains of mice. **Tumor** vaccine had a significant inhibitory effect on **tumor** appearance. *Vibrio cholera* **neuraminidase** treated

→
viable **tumor** cells delayed or prevented the appearance of **tumors**. **Neuraminidase** when **injected** directly into the **tumor** challenge site delayed the appearance and arrested the growth of **tumors**. **Neuraminidase** and mitomycin C treated **tumor** cells mixed with BCG had a marked inhibitory effect on **tumor** growth and this **treatment** was more effective.

DESCRIPTORS: VIBRIO-CHOLERAE CARCINOGEN FIBRO SARCOMA MITOMYCIN C ANTI NEOPLASTIC-DRUGS

CONCEPT CODES:

10808 Enzymes-Physiological Studies
18006 Bones, Joints, Fasciae, Connective and Adipose Tissue-Pathology
22012 Pharmacology-Connective Tissue, Bone and Collagen-Acting Drugs
22018 Pharmacology-Immunological Processes and Allergy
24003 Neoplasms and Neoplastic Agents-Immunology
24008 Neoplasms and Neoplastic Agents-Therapeutic Agents; Therapy
34504 Immunology and Immunochemistry-Bacterial, Viral and Fungal
34508 Immunology and Immunochemistry-Immunopathology, Tissue Immunology

36002 Medical and Clinical Microbiology-Bacteriology
38502 Chemotherapy-General; Methods; Metabolism
02506 Cytology and Cytochemistry-Animal
10060 Biochemical Studies-General
10064 Biochemical Studies-Proteins, Peptides and Amino Acids
12512 Pathology, General and Miscellaneous-Therapy (1971-)
22100 Routes of Immunization, Infection and Therapy
22501 Toxicology-General; Methods and Experimental
24005 Neoplasms and Neoplastic Agents-Neoplastic Cell Lines
24007 Neoplasms and Neoplastic Agents-Carcinogens and Carcinogenesis
31000 Physiology and Biochemistry of Bacteria
32500 Tissue Culture, Apparatus, Methods and Media

BIOSYSTEMATIC CODES:

06200 Actinomycetales (1969-78)
08200 Pseudomonadales (1969-78)
86375 Muridae

BIOSYSTEMATIC CLASSIFICATION (SUPER TAXA):

Microorganisms
Bacteria
Animals
Chordates
Vertebrates
Nonhuman Vertebrates
Mammals
Nonhuman Mammals
Rodents

8/9/46 (Item 10 from file: 73)
DIALOG(R) File 73:EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.

01525495 EMBASE No: 1979247489
Immunotherapy of neoplastic diseases with **neuraminidase**:
contradictions, new aspects, and revised concepts
Sedlacek H.H.; Seiler F.R.
Res. Lab. Behringwerke AG, D-3550 Marburg/Lahn Germany
Cancer Immunology Immunotherapy (CANCER IMMUNOL. IMMUNOTHER.) (Germany)
1978, 5/3 (153-163)
CODEN: CIIMD
DOCUMENT TYPE: Journal
LANGUAGE: ENGLISH

The divergent experimental results in immunotherapy of spontaneous, chemically induced or virus-induced solid **tumors** or leukemias with **neuraminidase** are reviewed and analyzed under the various aspects of the possible modes and conditions of action of the enzyme: Immunocompetence of the host, animal residual **tumor** volume, enzymatic activity of the **neuraminidase**, and identity of the antigenic specificity within the **tumor** system are well-known prerequisites for an effective **tumor** immunotherapy. In addition, there seems to be evidence that the number of **tumor** cells used for vaccination and the dose of enzymatically active VCN, whether bound to VCN-treated **tumor** cells or **injected** intratumorally, may be decisive in the negative or positive outcome. Moreover, there are indications that a pre-existent sensitization against the so-called Thomsen-Friedenreich antigen, which seems to be unmasked after VCN **treatment** of cells, may influence the **tumor** therapeutic success. The effect of nonspecific immunostimulators given in addition to **neuraminidase** or to **neuraminidase**-treated cells is controversial. Thus, this combination cannot be recommended unless it is fully explored. To overcome the problem of the dependence of the **tumor** therapeutic effect on the dose of cells and the amount of

neuraminidase with respect to different tumors and different adjuvant treatments, a new immunization concept, named 'chessboard vaccination', has been proposed. The data obtained so far in vitro and in vivo with this chessboard vaccination are briefly reviewed. They show that chessboard vaccination might be of diagnostic as well as of therapeutic interest.

DRUG DESCRIPTORS:

*bcg vaccine; *sialidase

MEDICAL DESCRIPTORS:

*cancer immunotherapy

diagnosis; drug therapy; therapy; short survey; biological model; intratumoral drug administration

MEDICAL TERMS (UNCONTROLLED): vibrio cholera neuraminidase

CAS REGISTRY NO.: 9001-67-6 (sialidase)

SECTION HEADINGS:

037 Drug Literature Index

016 Cancer

026 Immunology, Serology and Transplantation

013 Dermatology and Venereology

8/9/61 (Item 25 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2002 Elsevier Science B.V. All rts. reserv.

00339846 EMBASE No: 1975112204

Phytomitogen and neuraminidase in the treatment of Ehrlich carcinoma in mice

Mobley J.R.; Graber C.D.; O'Brien P.H.; et al.

VA Hosp., Charleston, S.C. 29403 United States

RES.COMMUN.CHEM.PATH.PHARMACOL. 1974, 9/1 (155-162)

CODEN: RCDCB

DOCUMENT TYPE: Journal

LANGUAGE: ENGLISH

Intraperitoneal injection of phytohemagglutinin (PHA) and Vibrio cholerae neuraminidase (VCN) given in combination extended the mean survival time of mice bearing the Ehrlich ascites tumor up to 147% over controls. Combination treatment of mice bearing the solid form of this tumor yielded increased survival times up to 222% more than controls. Tumor weight loss in mice bearing the ascitic tumor coincided with leukocytosis in the animals following an initial leukopenia evoked probably by PHA. The role of VCN in these studies is not clear, but the synergistic activity of the two agents against the ascitic tumor does not preclude an immunoregressive role for VCN.

MANUFACTURER NAMES: difco; general biochemicals

DRUG DESCRIPTORS:

*sialidase; *phytohemagglutinin; *placebo

MEDICAL DESCRIPTORS:

*cancer; *cancer cell; *cancer graft; *cancer growth; *carcinoma; *drug comparison; *drug mixture; *drug toxicity; *ehrlich ascites tumor; *ehrlich ascites tumor cell; *immunotherapy; *leukocytosis; *leukopenia; *mouse; *drug therapy; *survival time; *vibrio cholerae intraperitoneal drug administration; microorganism; therapy; theoretical study

MEDICAL TERMS (UNCONTROLLED): phytohemagglutinin d

CAS REGISTRY NO.: 9001-67-6 (sialidase); 9008-97-3 (phytohemagglutinin)

SECTION HEADINGS:

037 Drug Literature Index

026 Immunology, Serology and Transplantation

016 **Cancer**

030 Clinical and Experimental Pharmacology

?